These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 25051981)

  • 1. EZH2 expression correlates with locoregional recurrence after radiation in inflammatory breast cancer.
    Debeb BG; Gong Y; Atkinson RL; Sneige N; Huo L; Gonzalez-Angulo AM; Hung MC; Valero V; Ueno NT; Woodward WA
    J Exp Clin Cancer Res; 2014 Jul; 33(1):58. PubMed ID: 25051981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simvastatin radiosensitizes differentiated and stem-like breast cancer cell lines and is associated with improved local control in inflammatory breast cancer patients treated with postmastectomy radiation.
    Lacerda L; Reddy JP; Liu D; Larson R; Li L; Masuda H; Brewer T; Debeb BG; Xu W; Hortobágyi GN; Buchholz TA; Ueno NT; Woodward WA
    Stem Cells Transl Med; 2014 Jul; 3(7):849-56. PubMed ID: 24833589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome.
    Gong Y; Huo L; Liu P; Sneige N; Sun X; Ueno NT; Lucci A; Buchholz TA; Valero V; Cristofanilli M
    Cancer; 2011 Dec; 117(24):5476-84. PubMed ID: 21713757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EZH2 overexpression in different immunophenotypes of breast carcinoma and association with clinicopathologic features.
    Guo S; Li X; Rohr J; Wang Y; Ma S; Chen P; Wang Z
    Diagn Pathol; 2016 Apr; 11():41. PubMed ID: 27113214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triple-negative subtype predicts poor overall survival and high locoregional relapse in inflammatory breast cancer.
    Li J; Gonzalez-Angulo AM; Allen PK; Yu TK; Woodward WA; Ueno NT; Lucci A; Krishnamurthy S; Gong Y; Bondy ML; Yang W; Willey JS; Cristofanilli M; Valero V; Buchholz TA
    Oncologist; 2011; 16(12):1675-83. PubMed ID: 22147002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased risk for distant metastasis in patients with familial early-stage breast cancer and high EZH2 expression.
    Alford SH; Toy K; Merajver SD; Kleer CG
    Breast Cancer Res Treat; 2012 Apr; 132(2):429-37. PubMed ID: 21614565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MARCKS protein overexpression in inflammatory breast cancer.
    Manai M; Thomassin-Piana J; Gamoudi A; Finetti P; Lopez M; Eghozzi R; Ayadi S; Lamine OB; Manai M; Rahal K; Charafe-Jauffret E; Jacquemier J; Viens P; Birnbaum D; Boussen H; Chaffanet M; Bertucci F
    Oncotarget; 2017 Jan; 8(4):6246-6257. PubMed ID: 28009981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular subtypes in patients with inflammatory breast cancer; a single center experience.
    Kertmen N; Babacan T; Keskin O; Solak M; Sarici F; Akin S; Arik Z; Aslan A; Ates O; Aksoy S; Ozisik Y; Altundag K
    J BUON; 2015; 20(1):35-9. PubMed ID: 25778293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preoperative Radiation Therapy for Chemorefractory Localized Inflammatory Breast Cancer.
    Rogé M; Kirova Y; Loap P; Amar S; Servagi S; Nebbache R; Rivin Del Campo E; Clatot F; Thureau S; Thariat J
    Pract Radiat Oncol; 2023; 13(6):e491-e498. PubMed ID: 37295726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular phenotypes of DCIS predict overall and invasive recurrence.
    Williams KE; Barnes NLP; Cramer A; Johnson R; Cheema K; Morris J; Howe M; Bundred NJ
    Ann Oncol; 2015 May; 26(5):1019-1025. PubMed ID: 25678586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes.
    Masuda H; Brewer TM; Liu DD; Iwamoto T; Shen Y; Hsu L; Willey JS; Gonzalez-Angulo AM; Chavez-MacGregor M; Fouad TM; Woodward WA; Reuben JM; Valero V; Alvarez RH; Hortobagyi GN; Ueno NT
    Ann Oncol; 2014 Feb; 25(2):384-91. PubMed ID: 24351399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EZH2 knockdown suppresses the growth and invasion of human inflammatory breast cancer cells.
    Mu Z; Li H; Fernandez SV; Alpaugh KR; Zhang R; Cristofanilli M
    J Exp Clin Cancer Res; 2013 Sep; 32(1):70. PubMed ID: 24294976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and prognostic relevance of EZH2 in breast cancer: A meta-analysis.
    Wang X; Hu B; Shen H; Zhou H; Xue X; Chen Y; Chen S; Han Y; Yuan B; Zhao H; Zhi Q; Kuang Y
    Biomed Pharmacother; 2015 Oct; 75():218-25. PubMed ID: 26271144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognostic role of EZH2 expression in rectal cancer patients treated with neoadjuvant chemoradiotherapy.
    Meng X; Huang Z; Wang R; Jiao Y; Li H; Xu X; Feng R; Zhu K; Jiang S; Yan H; Yu J
    Radiat Oncol; 2014 Aug; 9():188. PubMed ID: 25159232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aldehyde dehydrogenase 1 expression in inflammatory breast cancer as measured by immunohistochemical staining.
    Gong Y; Wang J; Huo L; Wei W; Ueno NT; Woodward WA
    Clin Breast Cancer; 2014 Jun; 14(3):e81-8. PubMed ID: 24461456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EZH2 and STAT6 expression profiles are correlated with colorectal cancer stage and prognosis.
    Wang CG; Ye YJ; Yuan J; Liu FF; Zhang H; Wang S
    World J Gastroenterol; 2010 May; 16(19):2421-7. PubMed ID: 20480530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prognosis and risk factors of 1 791 patients with breast cancer treated with breast-conserving surgery based on real-world data].
    Chen SY; Tang Y; Song YW; Wang SL; Jin J; Liu YP; Wang WH; Fang H; Ren H; Sun GY; Wang JY; Jing H; Zhang JH; Liu XF; Yu ZH; Li YX
    Zhonghua Zhong Liu Za Zhi; 2018 Aug; 40(8):619-625. PubMed ID: 30139034
    [No Abstract]   [Full Text] [Related]  

  • 18. Prognostic impact of the cancer stem cell related markers ALDH1 and EZH2 in triple negative and basal-like breast cancers.
    De Brot M; Rocha RM; Soares FA; Gobbi H
    Pathology; 2012 Jun; 44(4):303-12. PubMed ID: 22544210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Keratin 17 is overexpressed and predicts poor survival in estrogen receptor-negative/human epidermal growth factor receptor-2-negative breast cancer.
    Merkin RD; Vanner EA; Romeiser JL; Shroyer ALW; Escobar-Hoyos LF; Li J; Powers RS; Burke S; Shroyer KR
    Hum Pathol; 2017 Apr; 62():23-32. PubMed ID: 27816721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patterns of Recurrence and Predictors of Survival in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy, Surgery, and Radiation.
    Keilty D; Nezafat Namini S; Swain M; Maganti M; Cil TD; McCready DR; Cescon DW; Amir E; Fleming R; Mulligan AM; Fyles A; Croke JM; Liu FF; Levin W; Koch CA; Han K
    Int J Radiat Oncol Biol Phys; 2020 Nov; 108(3):676-685. PubMed ID: 32407932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.